Abstract
Background
Cancer immunotherapy uses one’s own immune system to fight cancerous cells. As immune system is hard-wired to distinguish self and non-self, cancer immunotherapy is predicted to target cancerous cells specifically, therefore is less toxic than chemotherapy and radiation therapy, two major treatments for cancer. Cancer immunologists have spent decades to search for the specific targets in cancerous cells.
Methods
Due to the recent advances in high throughput sequencing and bioinformatics, evidence has merged that the neoantigens in cancerous cells are probably the cancer-specific targets that lead to the destruction of cancer.We will review the transplantable murine tumor models for cancer immunotherapy and the bioinformatics tools used to navigate mouse genome to identify tumor-rejecting neoantigens.
Results
Several groups have independently identified point mutations that can be recognized by T cells of host immune system. It is consistent with the note that the formation of peptide-MHC I-TCR complex is critical to activate T cells. Both anchor residue and TCR-facing residue mutations have been reported. While TCR-facing residue mutations may directly activate specific T cells, anchor residue mutations improve the binding of peptides to MHC I molecules, which increases the presentation of peptides and the T cell activation indirectly.
Conclusions
Our work indicates that the affinity of neoepitopes for MHC I is not a predictor for anti-tumor immune responses in mice. Instead differential agretopic index (DAI), the numerical difference of epitope-MHC I affinities between the mutated and un-mutated sequences is a significant predictor. A similar bioinformatics pipeline has been developed to generate personalized vaccines to treat human ovarian cancer in a Phase I clinical trial.
Similar content being viewed by others
References
Al Seesi S, Tiagueu Y T, Zelikovsky A, Măndoiu I I (2014). Bootstrapbased differential gene expression analysis for RNA-Seq data with and without replicates. BMC Genomics, 15(8 Suppl 8): S2
Basombrio M A (1970). Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res, 30(10): 2458–262
Bentley D R, Balasubramanian S, Swerdlow H P, Smith G P, Milton J, Brown C G, Hall K P, Evers D J, Barnes C L, Bignell H R, Boutell J M, Bryant J, Carter R J, Keira Cheetham R, Cox A J, Ellis D J, Flatbush MR, Gormley N A, Humphray S J, Irving L J, Karbelashvili M S, Kirk S M, Li H, Liu X, Maisinger K S, Murray L J, Obradovic B, Ost T, Parkinson M L, Pratt M R, Rasolonjatovo I M, Reed M T, Rigatti R, Rodighiero C, Ross M T, Sabot A, Sankar S V, Scally A, Schroth G P, Smith M E, Smith V P, Spiridou A, Torrance P E, Tzonev S S, Vermaas E H, Walter K, Wu X, Zhang L, Alam M D, Anastasi C, Aniebo I C, Bailey D M, Bancarz I R, Banerjee S, Barbour S G, Baybayan PA, Benoit VA, Benson K F, Bevis C, Black P J, Boodhun A, Brennan J S, Bridgham J A, Brown R C, Brown A A, Buermann D H, Bundu A A, Burrows J C, Carter N P, Castillo N, Chiara E, Catenazzi MChang S, Neil Cooley R, Crake N R, Dada O O, Diakoumakos K D, Dominguez-Fernandez B, Earnshaw D J, Egbujor U C, Elmore D W, Etchin S S, Ewan M R, Fedurco M, Fraser L J, Fuentes Fajardo K V, Scott Furey W, George D, Gietzen K J, Goddard C P, Golda G S, Granieri P A, Green D E, Gustafson D L, Hansen N F, Harnish K, Haudenschild C D, Heyer N I, Hims MM, Ho J T, Horgan A M, Hoschler K, Hurwitz S, Ivanov D V, Johnson M Q, James T, Huw Jones T A, Kang G D, Kerelska T H, Kersey A D, Khrebtukova I, Kindwall A P, Kingsbury Z, Kokko-Gonzales P I, Kumar A, Laurent MA, Lawley C T, Lee S E, Lee X, Liao A K, Loch J A, Lok M, Luo S, Mammen R M, Martin J W, McCauley P G, McNitt P, Mehta P, Moon K W, Mullens J W, Newington T, Ning Z, Ling Ng B, Novo S M, O’Neill M J, Osborne M A, Osnowski A, Ostadan O, Paraschos L L, Pickering L, Pike A C, Pike A C, Chris Pinkard D, Pliskin D P, Podhasky J, Quijano V J, Raczy C, Rae V H, Rawlings S R, Chiva Rodriguez A, Roe P M, Rogers J, Rogert Bacigalupo M C, Romanov N, Romieu A, Roth R K, Rourke N J, Ruediger S T, Rusman E, Sanches-Kuiper R M, Schenker M R, Seoane J M, Shaw R J, Shiver M K, Short S W, Sizto N L, Sluis J P, Smith M A, Ernest Sohna Sohna J, Spence E J, Stevens K, Sutton N, Szajkowski L, Tregidgo C L, Turcatti G, Vandevondele S, Verhovsky Y, Virk S M, Wakelin S, Walcott G C, Wang J, Worsley G J, Yan J, Yau L, Zuerlein M, Rogers J, Mullikin J C, Hurles M E, McCooke N J, West J S, Oaks F L, Lundberg P L, Klenerman D, Durbin R, Smith A J (2008). Accurate whole human genome sequencing using reversible terminator chemistry. Nature, 456(7218): 53–59
Berman J N, Chiu P P L, Dellaire G (2014). Preclinical animal models for cancer genomics. In: Dellair G, Berman J N, Arceci R J, eds. Cancer Genomics: from Bench to Personalized Medicine, Elsevier Inc., 110–126
Bielas J H, Loeb K R, Rubin B P, True L D, Loeb L A (2006). From the Cover: Human cancers express a mutator phenotype. Proc Natl Acad Sci USA, 103(48): 18238–18242
Blanchard T, Srivastava P K, Duan F (2013). Vaccines against advanced melanoma. Clin Dermatol, 31(2): 179–190
Boland J F, Chung C C, Roberson D, Mitchell J, Zhang X, Im K M, He J, Chanock S J, Yeager M, Dean M (2013). The new sequencer on the block: comparison of Life Technology’s Proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum Genet, 132(10): 1153–1163
Bolger A M, Lohse M, Usadel B (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics, 30(15): 2114–2120
Boon T, van der Bruggen P (1996). Human tumor antigens recognized by T lymphocytes. J Exp Med, 183(3): 725–729
Castle J C, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, Koslowski M, Kuhn A N, Britten C M, Huber C, Türeci O, Sahin U (2012). Exploiting the mutanome for tumor vaccination. Cancer Res, 72(5): 1081–1091
Cheon D J, Orsulic S (2011). Mouse models of cancer. Annu Rev Pathol, 6(1): 95–119
Dranoff G (2012). Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol, 12(1): 61–66
Duan F, Duitama J, Al Seesi S, Ayres C M, Corcelli S A, Pawashe A P, Blanchard T, McMahon D, Sidney J, Sette A, Baker B M, Mandoiu I I, Srivastava P K (2014). Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med, 211(11): 2231–2248
Duan F, Lin Y, Liu C, Engelhorn ME, Cohen A D, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Wolchok J D, Houghton A N (2009). Immune rejection of mouse tumors expressing mutated self. Cancer Res, 69(8): 3545–3553
Duitama J, Srivastava P K, Măndoiu I I (2012). Towards accurate detection and genotyping of expressed variants from whole transcriptome sequencing data. BMC Genomics, 13(2 Suppl 2): S6
Feng J, Meyer C A, Wang Q, Liu J S, Shirley Liu X, Zhang Y (2012). GFOLD: a generalized fold change for ranking differentially expressed genes from RNA-seq data. Bioinformatics, 28(21): 2782–2788
Foley E J (1953). Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res, 13(12): 835–837
Gubin M M, Zhang X, Schuster H, Caron E, Ward J P, Noguchi T, Ivanova Y, Hundal J, Arthur C D, Krebber W J, Mulder G E, Toebes M, Vesely M D, Lam S S, Korman A J, Allison J P, Freeman G J, Sharpe A H, Pearce E L, Schumacher T N, Aebersold R, Rammensee H G, Melief C J, Mardis E R, Gillanders W E, Artyomov M N, Schreiber R D (2014). Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 515(7528): 577–581
Kim D, Langmead B, Salzberg S L (2015). HISAT: a fast spliced aligner with low memory requirements. Nat Methods, 12(4): 357–360
Langmead B, Trapnell C, Pop M, Salzberg S L (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol, 10(3): R25
Larsen M V, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M (2007). Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics, 8(1): 424
Li B, Dewey C N (2011). RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics, 12(1): 323
Liu J, Blake S J, Smyth MJ, Teng MW (2014). Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunology, 3(8): e22
Lundegaard C, Lund O, Nielsen M (2008). Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics, 24(11): 1397–1398
Lurquin C, Van Pel A, Mariamé B, De Plaen E, Szikora J P, Janssens C, Reddehase M J, Lejeune J, Boon T (1989). Structure of the gene of tum-transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell, 58(2): 293–303
Matsushita H, Vesely M D, Koboldt D C, Rickert C G, Uppaluri R, Magrini V J, Arthur C D, White J M, Chen Y S, Shea L K, Hundal J, Wendl M C, Demeter R, Wylie T, Allison J P, Smyth M J, Old L J, Mardis E R, Schreiber R D (2012). Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature, 482(7385): 400–404
McGranahan N, Furness A J, Rosenthal R, Ramskov S, Lyngaa R, Saini S K, Jamal-Hanjani M, Wilson G A, Birkbak N J, Hiley C T, Watkins T B, Shafi S, Murugaesu N, Mitter R, Akarca A U, Linares J, Marafioti T, Henry J Y, Van Allen E M, Miao D, Schilling B, Schadendorf D, Garraway L A, Makarov V, Rizvi N A, Snyder A, Hellmann M D, Merghoub T, Wolchok J D, Shukla S A, Wu C J, Peggs K S, Chan T A, Hadrup S R, Quezada S A, Swanton C (2016). Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 351(6280): 1463–1469
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo M A (2010). The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res, 20(9): 1297–1303
Monach P A, Meredith S C, Siegel C T, Schreiber H (1995). A unique tumor antigen produced by a single amino acid substitution. Immunity, 2(1): 45–59
Nicolae M, Mangul S, Măndoiu I I, Zelikovsky A (2011). Estimation of alternative splicing isoform frequencies from RNA-Seq data. Algorithms Mol Biol, 6(1): 9
Noguchi Y, Chen Y T, Old L J (1994). A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA, 91(8): 3171–3175
Nowell P C (1976). The clonal evolution of tumor cell populations. Science, 194(4260): 23–28
Pandey V, Nutter R C, Prediger E (2008). Applied Biosystems SOLiD™ System: Ligation-Based Sequencing. In: Janitz M, ed. Next Generation Genome Sequencing. Wiley-VCH Verlag GmbH & Co. KGaA. p. 29–42
Prehn R T, Main J M (1957). Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst, 18(6): 769–778
Roberts A, Trapnell C, Donaghey J, Rinn J L, Pachter L (2011). Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol, 12(3): R22
Robinson M D, McCarthy D J, Smyth G K (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26(1): 139–140
Schmieder R, Edwards R (2011). Quality control and preprocessing of metagenomic datasets. Bioinformatics, 27(6): 863–864
Schuler M M, Nastke M D, Stevanovikć S (2007). SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol Biol, 409: 75–93
Srivastava P K (2015). Neoepitopes of Cancers: Looking Back, Looking Ahead. Cancer Immunol Res, 3(9): 969–977
Thomas R K, Nickerson E, Simons J F, Jänne P A, Tengs T, Yuza Y, Garraway L A, LaFramboise T, Lee J C, Shah K, O’Neill K, Sasaki H, Lindeman N, Wong K K, Borras A M, Gutmann E J, Dragnev K H, DeBiasi R, Chen T H, Glatt K A, Greulich H, Desany B, Lubeski C K, Brockman W, Alvarez P, Hutchison S K, Leamon J H, Ronan M T, Turenchalk G S, Egholm M, Sellers WR, Rothberg J M, Meyerson M (2006). Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med, 12(7): 852–855
Tian S, Maile R, Collins E J, Frelinger J A (2007). CD8 + T cell activation is governed by TCR-peptide/MHC affinity, not dissociation rate. J Immunol, 179(5): 2952–2960
Trapnell C, Pachter L, Salzberg S L (2009). TopHat: discovering splice junctions with RNA-Seq. Bioinformatics, 25(9): 1105–1111
Yadav M, Jhunjhunwala S, Phung Q T, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung T K, Fritsche J, Weinschenk T, Modrusan Z, Mellman I, Lill J R, Delamarre L (2014). Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature, 515(7528): 572–576
Yates L R, Campbell P J (2012). Evolution of the cancer genome. Nat Rev Genet, 13(11): 795–806
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to this work.
Rights and permissions
About this article
Cite this article
Al Seesi, S., Das Mohapatra, A., Pawashe, A. et al. Finding neoepitopes in mouse models of personalized cancer immunotherapy. Front. Biol. 11, 366–375 (2016). https://doi.org/10.1007/s11515-016-1422-2
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s11515-016-1422-2

